Creo Medical Group PLC First clinical use of new Creo GI product (9927H)
09 December 2020 - 6:00PM
UK Regulatory
TIDMCREO
RNS Number : 9927H
Creo Medical Group PLC
09 December 2020
Creo Medical Group plc
("Creo" or the "Company")
First clinical use of new Creo GI product
MicroBlate(TM) Fine device used for successful pancreatic tumour ablation
Creo Medical Group plc (AIM: CREO), the medical device company
focused on the emerging field of surgical endoscopy, announces the
first in-man clinical use of its MicroBlate(TM) Fine device,
believed to be the world's smallest fine needle microwave ablation
device available for clinical practice. The device was used to
successfully ablate pancreatic tumour tissue under Endoscopic
Ultrasound guidance, without any procedural complications.
The MicroBlate(TM) Fine device has the same dimensions as a
routine biopsy needle, greatly reducing the risk of procedural
bleeding and allowing very accurate targeting of microwave ablation
in highly perfused organs such as the liver, kidney, lung as well
as the pancreas.
Craig Gulliford, Chief Executive Officer of Creo, commented: "
We are very pleased with the first in-man clinical use of the
MicroBlate(TM) Fine device, bringing fine needle microwave ablation
into clinical practice for the first time and in particular, as in
this case, in the hands of GI physicians. This is a fantastic
milestone for the Company and the entire Creo team. We look forward
to further clinical firsts and regulatory announcements related to
our increasing suite of GI devices. More importantly, however, this
milestone has helped improve the outcome and made a difference to
the life of another of our patients. "
This announcement contains price sensitive information.
Enquires:
Creo Medical Group plc investors.creomedical.com
Richard Rees (CFO) +44 (0)1291 606 005
Cenkos Securities plc +44 (0)20 7397 8900
Stephen Keys / Camilla Hume (NOMAD)
Michael Johnson / Russell Kerr (Sales)
Walbrook PR Ltd Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com
Paul McManus / Lianne Cawthorne Mob: +44 (0)7980 541 893 / +44 (0)7515
909 238
About Creo Medical
Creo Medical, founded in 2003, is a medical device company
focused on the development and commercialisation of minimally
invasive surgical devices, by bringing advanced energy to
endoscopy. The Company's mission is to improve patient outcomes by
applying microwave and RF energy to surgical endoscopy. Creo has
developed CROMA, an electrosurgical Advanced Energy Platform that
combines bipolar radiofrequency for precise localised cutting and
microwave for controlled coagulation. This technology provides
clinicians with flexible, accurate and controlled surgical
solutions.
The Company's strategy is to bring its CROMA Advanced Energy
Platform powered by its unique full spectrum kamaptive technology
to market, enabling a suite of medical devices which the Company
has designed, initially for the emerging field of GI therapeutic
endoscopy, an area with high unmet needs. The CROMA Advanced Energy
Platform will be developed further for bronchoscopy and laparoscopy
procedures. The Company believes its technology can impact the
landscape of surgery and endoscopy by providing a safer,
less-invasive and more cost-efficient option of treatment. An
overview of the Creo Medical device technology portfolio can be
seen here:
https://www.rns-pdf.londonstockexchange.com/rns/8918P_1-2020-6-14.pdf
For more information about Creo Medical please see our website,
www.creomedical.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCEAFAPELDEFAA
(END) Dow Jones Newswires
December 09, 2020 02:00 ET (07:00 GMT)
Creo Medical (LSE:CREO)
Historical Stock Chart
From Apr 2024 to May 2024
Creo Medical (LSE:CREO)
Historical Stock Chart
From May 2023 to May 2024